Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: A phase II randomized study
Open Access
- 1 February 2000
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 11 (2) , 231-233
- https://doi.org/10.1023/a:1008325110921
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Prolonged disease-free survival in relapsed/refractory low-grade lymphoma treated with fludarabine: a report of four casesBritish Journal of Haematology, 1998
- Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1998
- Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-hodgkin's lymphomaCancer, 1998
- 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1994
- Lack of Effect of 2-Chlorodeoxyadenosine Therapy in Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine TherapyNew England Journal of Medicine, 1994
- 2-Chlorodeoxyadenosine for Patients with B-Cell Chronic Lymphocytic Leukemia Resistant to FludarabineNew England Journal of Medicine, 1993
- Response to 2-Chlorodeoxyadenosine in Patients with B-Cell Chronic Lymphocytic Leukemia Resistant to FludarabineNew England Journal of Medicine, 1992
- Fludarabine phosphate for the treatment of low grade lymphoid malignancyBritish Journal of Cancer, 1991